Connect Biopharma (NASDAQ:CNTB – Get Free Report) announced its earnings results on Monday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports. The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.12 million.
Connect Biopharma Stock Down 5.1%
Shares of NASDAQ:CNTB opened at $0.64 on Tuesday. Connect Biopharma has a fifty-two week low of $0.60 and a fifty-two week high of $3.82. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $2.10. The company has a market cap of $40.49 million, a price-to-earnings ratio of -0.54 and a beta of 0.06.
Wall Street Analysts Forecast Growth
CNTB has been the subject of a number of recent research reports. Weiss Ratings cut shares of Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. HC Wainwright reissued a “buy” rating on shares of Connect Biopharma in a research report on Wednesday, October 28th. Leerink Partners began coverage on shares of Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 target price for the company. Canaccord Genuity Group reduced their target price on shares of Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, September 16th. Finally, BTIG Research decreased their target price on shares of Connect Biopharma to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Connect Biopharma has an average rating of “Moderate Buy” and an average price target of $5.88.
Read Our Latest Stock Analysis on CNTB
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Read More
- Five stocks we like better than Connect Biopharma
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
